|
Pharmacological Group: Antineoplastic, Active Principle: Azacitidine, Pharmaceutical Form: Injectable Po, Concentration/Dosage: 100, Unit: Mg, Volume: N/A, Presentation: Vial: N/A, Active Principle: Bevacizumab, Pharmaceutical Form: Injectable Solution, Concentration/Dosage: 25, Mg/Ml, Volume: 4Ml, Accessory: Not Located, Volume: 16Ml, Active Principle: Bleomycin Sulfate, Concentration / Dosage: 15, Unit: U, Volume: Not Applicable, Accessory: N / D, Active Principle: Bortezomib, Concentration / Dosage: 3, 5, 04/04/2025, Active Principle: Cabazitaxel, Concentration: 1, 60, 60 5Ml, Presentation: F / A, Accessory: Diluent, Active Principle: Carboplatin, Pharmaceutical Form: N / D, Concentration / Dosage: 150, Active Principle: Dacarbazine, Concentration / Dosage: 200, Accessory: Non -Applicable, Active Principle: Etooposid, Concentration / Dosage: 20, Volume: 5Ml, Pharmacological Group Active: Filgrastim, Concentration / Dosage: 300, Unit: Mcg, Volume: 1Ml, Active Principle: Fulvest, Concentration / Dosage: 50, Presentation: Filled Syringe, Active Principle: Gencitabine Hydrochloride, Concentration / Dosage: 1, Unit: G, Volume: 50Ml, Active Principle: Irinotecan, Pharmacological Group: Antineoplastic/Enzyme Inhibitors, Active Principle: Ixazomibe Citrate, Pharmaceutical Form: Hard Capsule, Concentration/Dosage: 4, Presentation: Form Supply: Unit, Active Principle: Methotrexate, Volume: 2Ml, Active Principle: Methotrexate Of Sodium, Pharmaceutical Form: For Injectable Solution Without Preservative, Concentration / Dosage: 500, Pharmacological Group: Immunostimulant, Active Principle: Mycobacterium Bovis, Pharmaceutical Form: Injectable Po, Concentration / Dosage: 40, Ampoule, Form Supply: Ampoule, Active Principle: Pemetrexede, Active Principle: 10 Ml, 50 Ml, 50 Ml, Active Principle: Trastuzumab, Concentration / Dosage: 440, Active Principle: Vimblastin Sulfate, Concentration / Dosage: 10, Active Principle: Vinistine Sulfate, Volume: 1 Ml, Presentation: Bottle / Ampoule
|
